ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 458

First Year Canadian Experience with Subcutaneous Abatacept in Routine Practice for the Treatment of Patients with Rheumatoid Arthritis: Data from the Orencia Response Program (ORP) Network

Boulos Haraoui1, Louis Coupal2, Radmila Day3, Lionel Budry4 and Youb Chalabi5, 1Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, 2Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, 3None, Montreal, QC, Canada, 4Bristol Myers Squibb Canada, St-Laurent, QC, Canada, 5Bristol Myers Squibb, Montreal, QC, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Abatacept, rheumatoid arthritis (RA) and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The subcutaneous (SC) formulation
of abatacept (ABA) has been available in Canada since January 2014. Here we
report first year experience with SC ABA in Canadian RA patients (pts).
Canadian guidelines recommend the use of anti-TNFs or other mode of action biologics,
including abatacept, after inadequate response to DMARD.1 Furthermore,
the availability of an SC formulation of a biologic increases the treatment
options available to pts, particularly those wishing to self-administer their
therapy.

Methods: Canadian RA patients who accepted
treatment with abatacept (Orencia®) were enrolled in the Orencia® Response
Program (ORP) registry. RA pts treated with SC ABA in routine practice between
Jan – Dec 2014, were included in this analysis.  Durability of treatment with SC
ABA was assessed using Kaplan-Meier survival analysis.

Results: As of December 2014, a total of 1152 pts received
SC ABA. Out of these, 698 (61%) received SC ABA as the first or second line
biologic therapy and 454 (39%) as third or fourth line. The median age of pts
prescribed SC ABA was 60 years (range 16-89); 79.3% were females; and the
median time since diagnosis for the entire cohort was 11 years. 72% of pts had
severe and 23% had moderate disease. The majority of pts received their treatment
at home (68%), followed by rheumatology (12%) or ORP clinic (7%). Only 12 (1%)
of pts received the treatment at a doctor’s office. 12-month persistence rates
were similar in biologic naïve and non-naïve patients: 76.7% (SD=3.7%) for pts
receiving SC ABA first line (biologic naïve) and 73.6% (SD=2.2%) for biologic
experienced (non-naïve pts), Figure 1.

Conclusion: This data demonstrate that SC ABA can be
used early in the course of the disease (first or second line biologic therapy)
as well as in patients who fail several previous lines of biologics. Treatment
with abatacept resulted in high 1-year persistency rates in both biologic naïve
pts as well as those who failed one or more previous lines of biologic therapy.
 

1Bykerk VP, et al. J Rheumatol.
2012;39(8):1559-1582.

Figure 1. First year persistency rates in patients receiving
SC abatacept

 


Disclosure: B. Haraoui, Abbvie, Celgene, Amgen, BMS, Janssen, Pfizer, Roche and UCB Pharma, 2,Abbvie, Celgene, Amgen, BMS, Janssen, Pfizer, Roche and UCB Pharma, 5; L. Coupal, None; R. Day, Bristol-Myers Squibb, 5; L. Budry, Bristol-Myers Squibb, 3; Y. Chalabi, Bristol-Myers Squibb, 3.

To cite this abstract in AMA style:

Haraoui B, Coupal L, Day R, Budry L, Chalabi Y. First Year Canadian Experience with Subcutaneous Abatacept in Routine Practice for the Treatment of Patients with Rheumatoid Arthritis: Data from the Orencia Response Program (ORP) Network [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/first-year-canadian-experience-with-subcutaneous-abatacept-in-routine-practice-for-the-treatment-of-patients-with-rheumatoid-arthritis-data-from-the-orencia-response-program-orp-network/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/first-year-canadian-experience-with-subcutaneous-abatacept-in-routine-practice-for-the-treatment-of-patients-with-rheumatoid-arthritis-data-from-the-orencia-response-program-orp-network/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology